Pulse: Patients treated with CellFX catheter show favorable vein isolation data

Pulse Biosciences announced favorable findings from the 60-day post-procedure evaluations for four initial patients treated in the Company’s CellFX nsPFA 360 degrees Cardiac Catheter First-In-Human Feasibility Study. “The 60-day remap results for the initial patients treated with the CellFX nsPFA 360 degrees Cardiac Catheter in this feasibility study reveal favorable durable pulmonary vein isolation data,” said Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, NY. “I look forward to sharing more details on the findings from this feasibility study, including the results of the 60-day mapping evaluation, at an upcoming scientific meeting. In the meantime, we are quite excited to continue to enroll and treat patients as we progress and assess this promising and novel CellFX nsPFA technology.”